Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gang An

Showing results (191-200 of 274) with videos related to

Pageof 28
Sort By:
Cancer Research Communications|September 8, 2023
Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction TreatmentJiahui Liu, Wenqiang Yan, Huishou Fan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 25, 2015
Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2- Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug PenetrationHoufu Liu, Na Yu, Sijie Lu, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Longitudinal genetically detectable minimal residual disease by fluorescence <i>in situ</i> hybridization confers a poor prognosis in myelomaJian Cui, Tengteng Yu, Rui Lv, et al.
Frontiers in Immunology|October 9, 2024
DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathwaysLanting Liu, Dasen Gong, Hao Sun, et al.
Leukemia|April 12, 2024
Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myelomaJian Cui, Yuntong Liu, Rui Lv, et al.
Anesthesiology|April 29, 2006
Geographic regional differences in rocuronium bromide dose-response relation and time course of action: an overlooked factor in determining recommended dosageAshraf A Dahaba, Seth I Perelman, David M Moskowitz, et al.
Blood Science (Baltimore, Md.)|August 7, 2023
Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myelomaTeng Fang, Hao Sun, Xiyue Sun, et al.
Blood|April 30, 2016
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironmentYu-Tzu Tai, Chirag Acharya, Gang An, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|April 3, 2017
Suppression of MicroRNA-383 Enhances Therapeutic Potential of Human Bone-Marrow-Derived Mesenchymal Stem Cells in Treating Spinal Cord Injury via GDNFGuo-Jun Wei, Gang An, Zuo-Wei Shi, et al.
Journal for Immunotherapy of Cancer|March 5, 2024
Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapyHesong Zou, Wei Liu, Xiaojuan Wang, et al.
Pageof 28

Showing results (191-200 of 274) with videos related to

Sort By:
Pageof 28
Cancer Research Communications|September 8, 2023
Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction TreatmentJiahui Liu, Wenqiang Yan, Huishou Fan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 25, 2015
Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2- Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug PenetrationHoufu Liu, Na Yu, Sijie Lu, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Longitudinal genetically detectable minimal residual disease by fluorescence <i>in situ</i> hybridization confers a poor prognosis in myelomaJian Cui, Tengteng Yu, Rui Lv, et al.
Frontiers in Immunology|October 9, 2024
DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathwaysLanting Liu, Dasen Gong, Hao Sun, et al.
Leukemia|April 12, 2024
Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myelomaJian Cui, Yuntong Liu, Rui Lv, et al.
Anesthesiology|April 29, 2006
Geographic regional differences in rocuronium bromide dose-response relation and time course of action: an overlooked factor in determining recommended dosageAshraf A Dahaba, Seth I Perelman, David M Moskowitz, et al.
Blood Science (Baltimore, Md.)|August 7, 2023
Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myelomaTeng Fang, Hao Sun, Xiyue Sun, et al.
Blood|April 30, 2016
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironmentYu-Tzu Tai, Chirag Acharya, Gang An, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|April 3, 2017
Suppression of MicroRNA-383 Enhances Therapeutic Potential of Human Bone-Marrow-Derived Mesenchymal Stem Cells in Treating Spinal Cord Injury via GDNFGuo-Jun Wei, Gang An, Zuo-Wei Shi, et al.
Journal for Immunotherapy of Cancer|March 5, 2024
Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapyHesong Zou, Wei Liu, Xiaojuan Wang, et al.
Pageof 28